Table 3.

Multivariable Analysis of DFS, Local Failure, and Regional or Distant Failure

	Local ± Other		Regional or Distant Failure		Disease-Free Survival
Factor	Hazard Ratio (95% CI)	P-value	Hazard Ratio (95% CI)	P-value	Hazard Ratio (95% CI)	P-value
Pre/peri-menopausal patients
Treatment
CT×3→RT	1.00		1.00		1.00
CT×6→RT	0.95 (0.61–1.48)	0.82	1.11 (0.78–1.59)	0.57	1.09 (0.84–1.41)	0.50
Nodal status
1–3 positive nodes	1.00		1.00		1.00
≥4 positive nodes	1.09 (0.65–1.82)	0.74	1.96 (1.34–2.87)	0.0005	1.74 (1.31–2.30)	0.0001
ER status
Negative	1.00		1.00		1.00
Positive	0.80 (0.50–1.28)	0.35	0.96 (0.61–1.48)	0.84	0.87 (0.65–1.16)	0.34
Age
< 40 years	1.00		1.00		1.00
≥ 40 years	0.50 (0.32–0.80)	0.003	0.76 (0.50–1.16)	0.21	0.63 (0.47–0.84)	0.002
Postmenopausal patients
Treatment
No initial CT	1.00		1.00		1.00
CT×3→RT	1.53 (0.77–3.01)	0.22	1.04 (0.66–1.64)	0.87	1.07 (0.79–1.46)	0.65
Nodal status
1–3 positive nodes	1.00		1.00		1.00
≥4 positive nodes	1.35 (0.65–2.78)	0.42	2.05 (1.28–3.27)	0.003	1.83 (1.32–2.54)	0.0003
ER status
Negative	1.00		1.00		1.00
Positive	0.70 (0.31–1.58)	0.39	0.87 (0.49–1.58)	0.66	0.69 (0.48–1.01)	0.06
Age
< 65 years	1.00		1.00		1.00
≥ 65 years	1.49 (0.70–3.15)	0.30	0.92 (0.52–1.64)	0.78	1.42 (1.00–2.03)	0.05

Abbreviations: CT, chemotherapy; ER, estrogen receptor; CT×3, 3 months initial chemotherapy; CT×6, 6 months initial chemotherapy; RT, radiotherapy